BMGL — Basel Medical Income Statement
0.000.00%
- $79.91m
- $81.62m
- SG$10.05m
- 70
- 15
- 42
- 37
Annual income statement for Basel Medical, fiscal year end - June 30th, SGD millions except per share, conversion factor applied.
2022 June 30th | 2023 June 30th | 2024 June 30th | |
---|---|---|---|
Period Length: | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS |
Standards: | IFRS | IFRS | IFRS |
Status: | Final | Final | Final |
Revenue | |||
Total Revenue | 10.7 | 9.7 | 10.1 |
Selling / General / Administrative Expenses | |||
Depreciation and Amortization | |||
Other Operating Expenses | |||
Total Operating Expenses | 6.33 | 5.41 | 5.63 |
Operating Profit | 4.33 | 4.29 | 4.42 |
Total Net Non Operating Interest Income / Expense | |||
Other Net Non Operating Costs | |||
Net Income Before Taxes | 2.39 | 2.13 | 2.4 |
Provision for Income Taxes | |||
Net Income After Taxes | 1.98 | 1.78 | 2.07 |
Net Income Before Extraordinary Items | |||
Net Income | 1.98 | 1.78 | 2.07 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||
Income Available to Common Shareholders Including Extraordinary Items | |||
Diluted Net Income | 1.98 | 1.78 | 2.07 |
Diluted Weighted Average Shares | |||
Basic EPS Including Extraordinary Items | |||
Diluted EPS Including Extraordinary Items | |||
Diluted EPS Excluding Extraordinary Items | |||
Normalised Income Before Taxes | |||
Normalised Income After Taxes | |||
Normalised Income Available to Common Shareholders | |||
Diluted Normalised EPS | 0.107 | 0.097 | 0.112 |